76 results about "Leukemia cell line" patented technology

Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

Patients who develop increased numbers of γδ+ cytotoxic T lymphocytes 2–6 months after allogeneic bone marrow transplantation are less likely to relapse than those who do not. The γδ+ T cells isolated from blood of patients with increased γδ+ T cells are CD3+CD4−CD8−CD57+, cytolytic to K562 cells, and express the Vδ1 T cell receptor phenotype. Similar γδ+ T cells can be generated in vitro by culture of donor mononuclear cells which are enriched for γδ+ T cells by immunomagnetic depletion of depleted of CD4+ and CD8+ cells. This γδ-enriched cell preparation was cultured on a combination of immobilized pan-δ monoclonal antibody and irradiated recipient B cell leukemia. After four weeks, the cultures were almost exclusively Vδ1+CD3+CD4−CD8− cells that co-expressed activation-associated antigens CD69, CD25, and HLA-DR. Furthermore, they were cytolytic against the primary leukemia obtained from the recipient and lymphoblastic leukemia cell lines, yet had minimal cytotoxicity against normal donor-derived mononuclear cells or myeloid leulemia cell lines. These observations suggest that donor-derived cytotoxic γδ+ T cells can be generated in vitro, and may provide therapeutic potential for prevention of disease relapse.

The invention provides a human acute B lymphocyte leukemia cell line HXEX-ALL1. The human acute B lymphocyte leukemia cell line is preserved in China Center for Type Culture Collection (CCTCC) on October 25, 2017, and the preservation number is CCTCC NO: C2017232. The cell line is a primary line-established human acute B lymphocyte leukemia cell line and is a human acute B lymphocyte leukemia cellline with high tumorigenicity. The cell line provides a novel cell model for researches of relapse and refractory human acute lymphocyte leukemia and researches and development of biomedicines; the cell line can be provided for establishing a humanized acute lymphocyte leukemia animal model, an acute lymphocyte leukemia generation mechanism and relapse and refractory mechanism research platform,an acute lymphocyte leukemia novel drug research and development and screening platform, an acute lymphocyte leukemia immunological and microbiological research platform and the like. The human acuteB lymphocyte leukemia cell line HXEX-ALL1 provided by the invention has a wide prospect and relatively great application value for exploring a human acute lymphocyte leukemia pathogenesis, a relapse and refractory mechanism and drug research, development and application.

The invention discloses application of miR-638 in resisting myelogenous leukemia, and belongs to the field of molecular biology. Experiments indicate that in the processes of normal hematopoietic cell differentiation and development as well as acute myelogenous leukemia occurrence and development, the expression level of miR-638 has remarkable changes; in leukemic cell lines and primary acute myelogenous leukemia cells, the expression level of the miR-638 is up-regulated or down-regulated, and the cell differentiation process can be remarkably promoted or inhibited. Researching results indicate that the aim of treating acute myelogenous leukemia can be achieved by up-regulating the expression of the miR-638. Medicines for resisting acute myelogenous leukemia can be prepared from the miR-638, or the analog or expression vector of the miR-638 based on the functions of the miR-638. Important foundation is provided to development of novel acute myelogenous leukemia resisting medicines or diagnostic reagents.

The invention provides a preparation method of apoptotic vesicle. The preparation method comprises the following steps: 1) culturing a mouse mononuclear macrophage leukemia cell line in vitro; (2) when the confluence degree of the cells reaches 90%-100%, adding STS (staurosporin) to induce cell apoptosis; and (3) collecting the supernatant of the culture solution, and then separating the supernatant by virtue of a gradient centrifugation method, so as to obtain the apoptotic vesicle (apoVs). The invention also provides the apoptotic vesicle and application of the apoptotic vesicle in preparation of a preparation for promoting adipogenic differentiation of mesenchymal stem cells. The apoptotic vesicle provided by the invention can promote adipogenic differentiation of mesenchymal stem cells, can be used for repairing soft tissue defects or recesses, and have no obvious side effects.

The invention belongs to the technical field of medicines and relates to novel pyridone alkaloid extracted and separated from a fermented product of a plant endophytic fungus (Trametes) and application thereof in preparing a tumor cell inhibitor. The pyridone alkaloid compound has a chemical structural formula I. The experiments verify that the compound has a relatively good growth inhibiting effect on a human promyelocytic leukemia cell line HL-60 and a human breast cancer cell MCF-7, and the compound is simple and feasible in preparation method and good in reproducibility, so that further pharmacological and clinical researches on the compound are facilitated, and application of the compound in preparing the tumor cell inhibitor is developed. The formula is shown in the specification.

The invention discloses an indoledione piperazine type alkaloid and a preparing method and application thereof. The alkaloid is obtained from fermentation products of a garcinia multiflora endophyticfungus through separation and purification, wherein the endophytic fungus has the name of Aspergillus sp.GZWMJZ-258, is preserved in the China Center for Type Culture Collection on April 28th, 2019 atthe address of Wuhan, China, and has the preservation number of CCTCC NO:M 2019305. The indoledione piperazine type alkaloid is a compound with a new framework. It is shown through a pharmacologicalexperiment that the alkaloid has a certain selective retraining effect on a leukemia cell line MV4-11 and can be applied in an anti-leukemia medicine.

The present invention relates to vibsanin B, a preparation method and uses thereof. The vibsanin B preparation method comprises: (1) crushing dried viburnum awabuki branches and leaves, extracting with acetone, concentrating, adding water, dispersing, extracting with ethyl acetate, combining the organic phase, and concentrating to obtain a crude extract; (2) loading the crude extract onto a silica gel column chromatography segment; (3) decolorizing and removing large polar components through polyamide medium pressure column chromatography; and (4) purifying through normal phase column chromatography to obtain the vibsanin B. The present invention further provides the uses of the vibsanin B in preparation of anti-inflammatory drugs and anti-leukemia drugs. According to the present invention, the vibsanin B provides significant anti-inflammatory activity in the transgenic zebrafish inflammation model, and provides significant inhibition effects on leukemia cell line Kasumi-1 cell proliferation.

The invention relates to a novel triterpene compound extracted and separated from rosy south fructus schisandrae root and application of the compound to preparing of inhibitors of human promyelotic leukemia cell lines HL-60. The compound has a structure as shown in the formula I described in the specification. Experimental researches show that the compound has the growth inhibition action on the human promyelotic leukemia cell lines HL-60. Furthermore, a method for extracting and separating the compound is simple and easy; and the method is advantageous for carrying out further pharmacology and clinical research and developing the application of the compound to preparing of anti-tumour drugs.

The invention relates to an emodin quaternary phosphonium salt derivative with antitumor activity, a synthesis method therefor and an application of the emodin quaternary phosphonium salt derivative. The emodin quaternary phosphonium salt derivative is {10-[(4,5-dihydroxyl-7-methyl-9,10-anthraquinon-2-yl)oxo]decyl}phosphonium triphenylbromide. Proven by experiments, the emodin quaternary phosphonium salt derivative plays a certain role in inhibiting leukemia cells and solid tumor cells and can be used for preparing antitumor drugs. The emodin quaternary phosphonium salt derivative with antitumor activity, the synthesis method therefor and the application of the emodin quaternary phosphonium salt derivative have the following advantages that the synthesis method for the emodin quaternary phosphonium salt derivative, disclosed by the invention, is simple and is moderate in conditions; shown by the experiments, the emodin quaternary phosphonium salt derivative plays a certain role in inhibiting tumor cells, particularly HL-60 cells, Molt-4 cells, human chronic medullary system leukemia cell line K-562 cells, PANC-1 cells, Bax-PC3 cells, human liver cancer cells HepG2 and human lung cancer cells A549; and lipophilic emodin quaternary phosphonium salts have an application prospect in becoming anticancer drugs.

The invention belongs to the technical field of medicine and discloses a preparation method of a cell synergistic compound. The preparation method of the cell synergistic compound comprises the following steps: preparing glycyrrhetinic acid with the concentration of 89.04 [mu]mol/L to 96.8 [mu]mol/L; preparing ophiopogonpolysaccharide with the concentration of 800 [mu]g/mL, atractylodes macrocephalaon polysaccharide with the concentration of 800 [mu]g/mL and saposhnikovia divaricata polysaccharide with the concentration of 800 [mu]g/mL; preparing chebulinic acid with the concentration of 0.04mmol/L to 0.09 mmol/L and tellimagrandin I with the concentration of 0.04 mmol/L to 0.09 mmol/L; mixing and adding into a serum-free culture medium to perform cultivation. The glycyrrhetinic acid hasin vitro proliferation and inhibition effects on a myelogenous leukemia cell line K562, the change of cell cycle caused by the glycyrrhetinic acid is analyzed, and the possible anti-cancer mechanism is discussed; three kinds of traditional Chinese herbal medicine polysaccharide of radix ophiopogonis, bighead atractylodes rhizome and radices sileris are adopted, and the influence of crude ophiopogonpolysaccharide POJ on the proliferation and inhibition effect of leukemia cell K562 cells is detected by an MTT method.

The invention discloses an hsa-MiR-146a-5p gene PCR detection kit and application thereof, that kit comprise hsa-MiR- 146a-5p gene reverse transcription reaction solution, MMLV reverse transcriptase,RNase inhibitor, PCR reaction solution, Taq enzyme, hsa-MiR-146a-5p gene specific prim, probe, positive control and negative control; Using the hsa-MiR-146a- 5p, that accuracy of drug resistance of leukemia cell line could reach more than 80%, As that agent use in the invention, including enzyme, buffer, primer, probe and the like, are carefully designed and optimized, the accuracy of gene expression detection is greatly improve.

The invention relates to the field of organic synthesis and medicines and discloses an N-(4-fluorobenzyl)-3, 5-bis(4-trifluoromethyl benzylidene)-4-piperodone. A preparation method comprises the steps of: sequentially carrying out Michael addition, Diecmann condensation, acidolysis and decarboxylation on 4-flunamine and methyl acrylate to obtain N-(4-fluorobenzyl)-4-piperodone, and carrying out aldol condensation reaction between N-(4-fluorobenzyl)-4-piperodone and 4-trifluoromethylbenzaldehyde to obtain the target compound N-(4-fluorobenzyl)-3, 5-bis(4-trifluoromethyl benzylidene)-4-piperodone. The target compound can be used for efficiently and selectively inhibiting proliferation of 12 leukemic cell lines, and the cell lines of ovarian cancers, breast cancers, liver cancers, esophageal cancers and the like and has lower toxicity on normal hematopoietic stem cells; and the activity of inhibiting the cancer cell line proliferation of the target compound is obviously higher than that of the traditional chemotherapeutics 5-fluorouracil.

The invention discloses a construction method of an acute lymphocytic leukemia mouse model. The construction method comprises the following steps of preparing leukemia cell line suspension with high expression of ERG, knocking down ERG protein expression of the cell line by using shERG packaged by lentivirus, transfecting Luciferase into a wild type and shERG cell line by lentivirus, inoculating the cell line into an immunodeficient mouse, evaluating the tumor process by using a small animal imaging system, and evaluating the treatment effect of a specific drug on the acute lymphocytic leukemia with high expression of ERG by using the small animal imaging system and a flow analysis method, and the like. The model evaluates the efficacy of a specific drug on a subtype of acute lymphocytic leukemia. According to the disease model construction method provided by the invention, the tumor development process of the model animal can be directly and noninvasively evaluated, and the success rate is very high. In addition, the disease model established according to the method provided by the invention has very high clinical correlation.

The invention belongs to the technical field of leukemia cell lines, and provides an atypical chronic myeloid leukemia cell line NT-1 of which the collection number is CCTCC NO:C2013103, and the atypical chronic myeloid leukemia cell line NT-1 is collected in the China center for type culture collection on August 1, 2013. The invention further provides a preparation method and application of the leukemia cell line NT-1. A new ideal is provided for diagnosis and treatment of atypical chronic myeloid leukemia, and the atypical chronic myeloid leukemia cell line and the preparation method have significance on early diagnosis and drug screening of the atypical chronic myeloid leukemia.